Media – Abzena


Annual Report 2017

Abzena PLC’s Annual Report 2017



World ADC San Diego

20 September 2017

Widen the Therapeutic Index of Your ADC Program World ADC San Diego is the definitive industry forum for accelerating the[...] Read more

American Biomanufacturing Summit

23 May 2017

Abzena is attending The American Biomanufacturing Summit is one of the most senior-level conferences and networking[...] Read more


A deimmunised form of the ribotoxin, α-sarcin, lacking CD4+ T cell epitopes and its use as an immunotoxin warhead

Fungal ribotoxins that block protein synthesis can be useful warheads in the context of a targeted immunotoxin. α-Sarcin[...] Read more


Full year results: integration and growth seen across the Group, with 41% underlying increase in revenues

Cambridge, UK, 13 June 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group[...] Read more

Bioverativ to acquire True North Therapeutics and the Abzena Inside portfolio product, TNT009

Cambridge, UK, 24 May 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing[...] Read more


We’re changing the way we brand our businesses

To provide our Partners with a single identity for the services and technologies offered across Antitope, PacificGMP,[...] Read more

Interested in our services? Get In Touch